Verastem Oncology (NASDAQ: VSTM) presented COPIKTRA data showing response rates of 44% to 57%, including complete response rates of 15% to 22% in patients with relapsed or refractory peripheral T-cell lymphoma.
Verastem is a biopharmaceutical company focused on developing medicines to improve the survival and quality of life of cancer patients. COPIKTRA is also being developed by for the treatment of peripheral T-cell lymphoma.
“Although the patient numbers are small in these two Phase 1 studies, we see a positive trend in response rates,” said Steven Horwitz, Memorial Sloan Kettering Cancer Center, co-principal investigator of the Phase 1 and 2 studies, and lead author of the oral presentation.
Verastem shares traded higher by 2.5% at $1.63 in Friday's pre-market session.
The Daily Biotech Pulse
CarMax Shares Trade Higher After Positive Q1 Earnings
See more from Benzinga
- Thomson Reuters To Acquire Audit Service Company Confirmation
- Red Hat Reports Q1 Earnings Beat
- Korn Ferry Falls On Lower Guidance
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.